The Ritchie Centre, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia.
Br J Pharmacol. 2011 Nov;164(5):1397-9. doi: 10.1111/j.1476-5381.2011.01488.x.
Despite the well-known harmful effects, many women continue to smoke throughout pregnancy. Consequently, nicotine replacement therapy (NRT) - which has been developed as a pharmacotherapy for smoking cessation - has been used as an alternative to smoking during pregnancy. However, like cigarette smoking, NRT results in biologically significant levels of nicotine crossing the placenta, leading to both fetal and neonatal exposure to nicotine, and yet, NRT safety during pregnancy has not been extensively evaluated. There is now evidence from studies in rats that maternal nicotine exposure throughout gestation results in fetal programming of vascular oxidative stress in the offspring during adulthood. This phenomenon involves vascular dysfunction mediated by reactive oxygen species in association with decreased superoxide dismutase activity and increased Nox2-NADPH oxidase expression in the vascular wall. If this phenomenon also occurs in humans, either smoking or NRT use during pregnancy may represent a novel risk factor for the unborn that results in accelerated cardiovascular disease in their adulthood.
尽管众所周知吸烟有害,但许多女性仍在整个孕期继续吸烟。因此,尼古丁替代疗法(NRT)已被开发为戒烟的药物治疗方法,被用作怀孕期间替代吸烟的方法。然而,与吸烟一样,NRT 会导致生物意义上的尼古丁穿过胎盘,导致胎儿和新生儿暴露于尼古丁,而 NRT 在怀孕期间的安全性尚未得到广泛评估。现在有来自大鼠研究的证据表明,母亲在整个孕期接触尼古丁会导致成年后代的血管氧化应激发生胎儿编程。这种现象涉及到与血管壁中超氧化物歧化酶活性降低和 Nox2-NADPH 氧化酶表达增加有关的活性氧介导的血管功能障碍。如果这种现象也发生在人类身上,那么怀孕期间吸烟或使用 NRT 可能代表一个新的胎儿风险因素,导致他们成年后加速患心血管疾病。